COMP <GO>
HALO vs MRK // FREE CASH FLOW YIELD
Halozyme Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: HALO 4
— MRK 9
▲ FREE CASH FLOW YIELD LEADER: HALO
LAST: $128.95 (-1.50%) • MKT CAP: $14.64B
fcf-yield
4.33%
LAST: $148.36 (-0.78%) • MKT CAP: $366.03B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HALO | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.60% | 74.80% | +8.80 | HALO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.00% | 20.70% | -2.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.6x | 15.3x | +20.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.33% | 3.42% | +0.91 | HALO | /fcf-yield <GO> |
| Operating Margin | 33.60% | 34.30% | -0.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 22.70% | 28.10% | -5.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 37.60% | 1.30% | +36.30 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.11 | 5.19 | -0.08 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.2 | 54.3 | +14.90 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.92 | -0.04 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.5x | 18.4x | +21.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.64B | $366.03B | -$351.39B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HALO REV | MRK REV | HALO GROSS % | MRK GROSS % | HALO FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $65.01B | 83.6% | 74.8% | $644.6M | $12.36B |
| FY 2024 | $1.02B | $64.17B | 84.3% | 76.3% | $468.4M | $18.10B |
| FY 2023 | $829.3M | $60.12B | — | — | $351.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
MRK // BETA 0.92